Influence of Adherent and Effective Antiretroviral Therapy Use on Human Papillomavirus Infection and Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-positive Women

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2010 Jan 29

PMID 20105077

Citations 73

Authors

Howard Minkoff

Ye Zhong

Robert D Burk

Joel M Palefsky

Xiaonan Xue

D Heather Watts

Alexandra M Levine

Rodney L Wright

Christine Colie

Gypsyamber DSouza

L Stewart Massad

Howard D Strickler

Affiliations

Soon will be listed here.

Abstract

Background: The impact of highly active antiretroviral therapy (HAART) on the natural history of human papillomavirus (HPV) remains uncertain following conflicting reports. Prior studies, however, did not consider patients' adherence to their regimens or HAART effectiveness (viral suppression).

Methods: Human immunodeficiency virus (HIV)-positive women (N = 286) who initiated HAART during follow-up in a prospective cohort were assessed semiannually for HPV infection (by polymerase chain reaction) and squamous intraepithelial lesions (SILs). Adherence was defined as use of HAART as prescribed > or = 95% of the time, and effective HAART was defined as suppression of HIV replication. The prevalence, incident detection, and clearance of HPV infection and/or SILs before versus after HAART initiation were compared (using women as their own comparison group).

Results: HAART initiation among adherent women was associated with a significant reduction in prevalence (odds ratio, 0.60 [95% confidence interval {CI}, 0.44-0.81]; P = .001), incident detection of oncogenic HPV infection (hazard ratio [HR], 0.49 [95% CI, 0.30-0.82]; P = .006), and decreased prevalence and more rapid clearance of oncogenic HPV-positive SILs (HR, 2.35 [95% CI, 1.07-5.18]; P = .03). Effects were smaller among nonadherent women. The associations of HPV infection and/or SILs with HAART effectiveness were fairly similar to those with HAART adherence.

Conclusion: Effective and adherent HAART use is associated with a significantly reduced burden of HPV infection and SILs; this may help explain why rates of cervical cancer have not increased during the HAART era, despite greater longevity.

Citing Articles

Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk.

Hewavisenti R, Arena J, Ahlenstiel C, Sasson S Front Immunol. 2023; 14:1112513.

PMID: 36960048 PMC: 10027931. DOI: 10.3389/fimmu.2023.1112513.

Persistence of High Percentage of Peripheral Activated CD8+ T Cells Predict Cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects.

Mondatore D, Bai F, Augello M, Giovenzana M, Pisani Ceretti A, Bono V Open Forum Infect Dis. 2022; 9(4):ofac046.

PMID: 35291446 PMC: 8918388. DOI: 10.1093/ofid/ofac046.

Impact of a delayed diagnosis of vulvar cancer and its association with HIV infection: A 4-year review at a tertiary hospital in KwaZulu-Natal, South Africa.

Hlapane R, Khumalo T, Makhathini B, Moodley J South Afr J HIV Med. 2021; 22(1):1272.

PMID: 34691768 PMC: 8517792. DOI: 10.4102/sajhivmed.v22i1.1272.

How Much Does HIV Positivity Affect the Presence of Oral HPV? A Molecular Epidemiology Survey.

Visalli G, Di Pietro A, Curro M, Ciarello M, DAndrea F, Nunnari G Int J Environ Res Public Health. 2021; 18(17).

PMID: 34501585 PMC: 8431652. DOI: 10.3390/ijerph18178999.

Cervical cancer prevention and control in women living with human immunodeficiency virus.

Castle P, Einstein M, Sahasrabuddhe V CA Cancer J Clin. 2021; 71(6):505-526.

PMID: 34499351 PMC: 10054840. DOI: 10.3322/caac.21696.

References

Strickler H, Burk R, Fazzari M, Anastos K, Minkoff H, Massad L . Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005; 97(8):577-86. DOI: 10.1093/jnci/dji073. View

Palefsky J . Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol. 2003; 15(5):382-8. DOI: 10.1097/00001622-200309000-00007. View

Minkoff H, Ahdieh L, Massad L, Anastos K, Watts D, Melnick S . The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS. 2001; 15(16):2157-64. DOI: 10.1097/00002030-200111090-00011. View

Ahdieh L, Gange S, Greenblatt R, Minkoff H, Anastos K, Young M . Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol. 2000; 152(10):923-33. DOI: 10.1093/aje/152.10.923. View

Rodriguez B, Sethi A, Cheruvu V, Mackay W, Bosch R, Kitahata M . Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006; 296(12):1498-506. DOI: 10.1001/jama.296.12.1498. View

Biggar R, Chaturvedi A, Goedert J, Engels E . AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007; 99(12):962-72. DOI: 10.1093/jnci/djm010. View

Barkan S, Melnick S, Preston-Martin S, Weber K, Kalish L, Miotti P . The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998; 9(2):117-25. View

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

Sirera G, Videla S, Lopez-Blazquez R, Llatjos M, Tarrats A, Castella E . Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era. AIDS Res Hum Retroviruses. 2007; 23(8):965-71. DOI: 10.1089/aid.2006.0293. View

10.

Strickler H, Palefsky J, Shah K, Anastos K, Klein R, Minkoff H . Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst. 2003; 95(14):1062-71. DOI: 10.1093/jnci/95.14.1062. View

11.

Xue X, Gange S, Zhong Y, Burk R, Minkoff H, Massad L . Marginal and mixed-effects models in the analysis of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev. 2010; 19(1):159-69. PMC: 2839537. DOI: 10.1158/1055-9965.EPI-09-0546. View

12.

Clifford G, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A . Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005; 97(6):425-32. DOI: 10.1093/jnci/dji072. View

13.

Del Mistro A, Bertorelle R, Franzetti M, Cattelan A, Torrisi A, Giordani M . Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis. 2004; 38(5):737-42. DOI: 10.1086/381681. View

14.

Davis A, Chakraborty H, Flowers L, Mosunjac M . Cervical dysplasia in women infected with the human immunodeficiency virus (HIV): a correlation with HIV viral load and CD4+ count. Gynecol Oncol. 2001; 80(3):350-4. DOI: 10.1006/gyno.2000.6104. View

15.

Ortiz R, DeJesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J . Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008; 22(12):1389-97. DOI: 10.1097/QAD.0b013e32830285fb. View

16.

Schuman P, Ohmit S, Klein R, Duerr A, Cu-Uvin S, Jamieson D . Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis. 2003; 188(1):128-36. DOI: 10.1086/375783. View

17.

Kapadia F, Vlahov D, Wu Y, Cohen M, Greenblatt R, Howard A . Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women. Am J Drug Alcohol Abuse. 2008; 34(2):161-70. DOI: 10.1080/00952990701877052. View

18.

Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine M . Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS. 1998; 12(12):1459-64. DOI: 10.1097/00002030-199812000-00007. View

19.

Mandelblatt J, Kanetsky P, Eggert L, Gold K . Is HIV infection a cofactor for cervical squamous cell neoplasia?. Cancer Epidemiol Biomarkers Prev. 1999; 8(1):97-106. View

20.

Minkoff H, Feldman J, Burk R, Clarke L . Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Am J Obstet Gynecol. 1999; 180(4):824-36. DOI: 10.1016/s0002-9378(99)70653-8. View